Cargando…

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartsch, Rupert, Berghoff, Anna Sophie, Furtner, Julia, Marhold, Maximilian, Bergen, Elisabeth Sophie, Roider-Schur, Sophie, Starzer, Angelika Martina, Forstner, Heidrun, Rottenmanner, Beate, Dieckmann, Karin, Bago-Horvath, Zsuzsanna, Haslacher, Helmuth, Widhalm, Georg, Ilhan-Mutlu, Aysegül, Minichsdorfer, Christoph, Fuereder, Thorsten, Szekeres, Thomas, Oehler, Leopold, Gruenberger, Birgit, Singer, Christian F., Weltermann, Ansgar, Puhr, Rainer, Preusser, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499862/ https://www.ncbi.nlm.nih.gov/pubmed/35941372 http://dx.doi.org/10.1038/s41591-022-01935-8

Ejemplares similares

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic
por: Fuereder, Thorsten, et al.
Publicado: (2020)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma
por: Starzer, Angelika Martina, et al.
Publicado: (2022)

Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial
por: Mair, Maximilian J., et al.
Publicado: (2023)

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016)

Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
por: Starzer, Angelika M., et al.
Publicado: (2022)

Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
por: Starzer, Angelika M., et al.
Publicado: (2021)

Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature
por: Leibetseder, Annette, et al.
Publicado: (2021)

Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
por: Wolff, Ladislaia, et al.
Publicado: (2023)

Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

New Approaches with Precision Medicine in Adult Brain Tumors
por: Leibetseder, Annette, et al.
Publicado: (2022)

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2018)

Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation
por: Steindl, Ariane, et al.
Publicado: (2020)

Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times
por: Berghoff, Anna Sophie, et al.
Publicado: (2013)

High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases
por: Leitner, Johannes, et al.
Publicado: (2018)

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
por: Mair, Maximilian J., et al.
Publicado: (2022)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2017)

SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES
por: Mercea, Petra Andreea, et al.
Publicado: (2019)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers
por: Berghoff, Anna Sophie, et al.
Publicado: (2012)

Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
por: Bergen, E.S., et al.
Publicado: (2021)

New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
por: Starzer, Angelika M., et al.
Publicado: (2020)

Deruxtecan-Induced Reversible Fanconi Syndrome
por: Kalantri, Pooja, et al.
Publicado: (2023)

Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012)

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
por: Füreder, L. M., et al.
Publicado: (2018)

Establishing end-of-life boards for palliative care of patients with advanced diseases
por: Masel, Eva K., et al.
Publicado: (2018)

Nachwuchsförderung durch die European Society for Medical Oncology (ESMO): Erfahrungen aus dem ESMO Young Oncologist Committee (YOC)
por: Oing, Christoph, et al.
Publicado: (2020)

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis
por: Puhr, H. C., et al.
Publicado: (2019)

Prognostic impact of genetic alterations and methylation classes in meningioma
por: Berghoff, Anna S., et al.
Publicado: (2022)

Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
por: Mair, Maximilian J., et al.
Publicado: (2022)

Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma
por: Furtner, Julia, et al.
Publicado: (2021)

EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells
por: Grandits, Alexander Michael, et al.
Publicado: (2022)

Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy
por: Minichsdorfer, Christoph, et al.
Publicado: (2022)

Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases
por: Steindl, Ariane, et al.
Publicado: (2020)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee
por: Kiesel, Barbara, et al.
Publicado: (2020)

Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling
por: Furtner, Julia, et al.
Publicado: (2019)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k0f9345u52q3aoh6vnb01djtq1